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1. Introduction
Tobacco smoking remains a major cause of preventable death
and disability. Quitting smoking is associated with considerable
improvements in mental and physical health and life expec-
tancy. All current smokers should be encouraged to quit smok-
ing and offered therapeutic options for smoking cessation.
Current pharmacotherapies have limited effectiveness, with
75% of smokers relapsing within 12 months of treatment and
only 4% to 7% successfully quitting permanently after a quit
attempt [1]. Reasons for relapse or failure to quit are highly
individualized. There is an urgent need for better therapies for
smoking cessation, either through more effective pharma-
cotherapies for population based approaches and/or through
the development of treatments that are individualized and
tailored to the specific needs and preferences of the individual
smoker. Further research is required to evaluate novel pharma-
cotherapies and individualised approaches that may have
greater efficacy or advantages in special populations.
Historically, major inroads in the reduction of tobacco use have
been achieved through population-based approaches, including;
public health messages, regulation of the tobacco industry and
tobacco products, restrictions on advertising, tobacco sales, and
smoking in public places, and the provision of services to assist
smokers to quit. Pharmacotherapies have conformed to this same
model, developing treatment strategies that can be used as
broadly as possible. Efficacy studies of smoking cessation pharma-
cotherapies have generally focused on smokers in the general
community, although the focus has shifted to high prevalence
smokers such as those with psychiatric comorbidities [2]. More
recently, individualized therapies have been attracting attention,
and both individualized and population-based strategies are likely
to continue to play important roles in the future.
Therapies can also be refined to integrate them into win-
dows of opportunity for specific individuals. Opportunities for
intervention may arise during periods of medical treatment or
hospitalization or during reproductive events such as preg-
nancy. Advice from a doctor to quit smoking has been shown
to result in higher rates of quitting, as is the motivational
impact of a potentially smoking-related disorder [3]. Many
hospitalized patients are not able to smoke due to restrictions
on smoking in the hospital setting. A study of psychiatric in-
patients in a smoke-free hospital setting demonstrated the
importance of providing nicotine replacement therapy (NRT)
to avoid withdrawal and discharge against medical advice [4].
Abstinence from smoking while in hospital, as well as
increased motivation to quit provides an ideal opportunity
for intervention and there is evidence that a smoking cessa-
tion intervention after hospital discharge is associated with
higher rates of sustained abstinence [5]. Further research is
required to establish if higher quit rates can be achieved
through interventions managed by the same clinicians treat-
ing the physical illness, or in the same health-care setting
result in higher quit rates compared to referring patients to
smoking cessation treatments delivered elsewhere. Pregnancy
is also a window of opportunity for intervention as smokers
may be more motivated to quit if they are pregnant or con-
sidering pregnancy and a critical period due to concerns
about the safety of pharmacotherapeutic interventions.
2. Pharmacotherapeutic options for treating
nicotine dependence
Only three pharmacotherapeutic options are currently approved
by major regulatory authorities, such as the U.S. Food and Drug
administration and the European Medicines Agency as first-line
treatments. These are NRT, which comes in a range of products,
varenicline, and bupropion. Nortriptyline and clonidine are
recognized as second-line treatments. In addition, more than
40 pharmacotherapies have been investigated for smoking ces-
sation, with varying levels of evidence. Some of these therapies
appear promising and merit further investigation.
NRT as an effective smoking cessation aide, whether formu-
lated as gum, transdermal patch, nasal spray, inhaler or sub-
lingual tablets/lozenges, is evidenced by over 150 randomized
clinical trials totaling over 50,000 trial participants. NRTs
increase the chances of successfully stopping smoking for
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a quit attempt by 50% to 70% compared to placebo. Highly
dependent smokers showed greater benefit from 4 mg gum
than from 2 mg gum, but not from higher doses of patch.
Combining a patch with rapid delivery NRT was more effective
than a single type of NRT. Treatment with NRT was shown to be
as effective as bupropion, and combination NRT with bupro-
pion was more effective than bupropion monotherapy [6].
Meta-analyses suggest that varenicline and combined forms of
NRT are associated with higher quit rates than bupropion or
single-form NRT [7]. Varenicline was associated with greater
continuous abstinence from smoking during weeks 15 to 24
compared to placebo (37.8% for varenicline; 6.9% for placebo)
in an RCT of smokers willing to reduce cigarette consumption
and make a quit attempt within 3 months [8].
Electronic nicotine delivery systems (ENDS) have become
widely available and have rapidly increased in popularity.
Users reports suggest that they are used for smoking cessation
or reduction, harm minimisation, or recreational use [9]. There
is evidence to demonstrate the efficacy of ENDS for cessation
of tobacco smoking [10] suggesting that it may have a role as
a harm minimization strategy, possibly for heavy smokers who
are not contemplating quitting. There are concern and limited
evidence that ENDS use may be a gateway to tobacco use [11].
It is not possible to assess if there will be any future therapeu-
tic role for ENDS due to a paucity of long-term data and an
unclear regulatory framework.
In addition to NRT, varenicline, and bupropion, several
conventional pharmaceuticals with indications for other con-
ditions have been investigated as smoking cessation aides.
The tricyclic antidepressant nortriptyline and the antihyperten-
sive agent clonidine have both demonstrated superiority to
placebo for smoking cessation randomized controlled trials.
Their use in treatment can be considered depending on
patient preference, consideration of the risks of adverse
events, and comorbid medical conditions [12]. Trials of
Selective Serotonin Reuptake Inhibitors for smoking cessation
have failed to demonstrate efficacy, suggesting that the
mechanisms of action for nortriptyline and bupropion are
not through their antidepressant activity [1].
Emerging data suggests that some novel therapies merit
further investigation. These include; a pilot study of
N-acetylcysteine that showed superiority to placebo for quit
rates and reduced number of cigarettes smoked [13], and
cytisine in numerous small studies, meta-analyses, and a non-
inferiority trials versus NRT all suggesting efficacy [1].
Numerous other agents, including other conventional pharma-
ceuticals and alternative or natural therapies, have been inves-
tigated but were found not to be effective, or had
unacceptable risks, or do not have sufficient evidence to
suggest usefulness [1]. Other agents are still being trialed.
There is some data from rodent studies of kappa-opioid recep-
tor antagonists [14]. Non-pharmacological interventions can
also be effective, with offering financial incentive demonstrat-
ing great efficacy for smoking cessation than pharmacothera-
pies [15]. Adjunctive psychological approaches, including
telephone, internet or clinician support, are beneficial for peo-
ple attempting to quit. Clinical trials of nicotine vaccines have
so far failed to demonstrate efficacy for smoking cessation;
however, further vaccine development is continuing [16].
A decision tree for smoking cessation treatment allocation is
provided as Figure 1.
3. Targeted and individualized therapies
Individualized therapies are tailored to the characteristics and
preferences of the individual smoker. This can be characteris-
tics of smoking behavior, motivation to quit, or characteristics
of special populations. There is some data to suggest that
heavy or highly dependent smokers can benefit from higher
dose of NRT [6] or more intensive interventions [17] as sug-
gested by 3-week inpatient intervention for heavy smokers.
Nicotine metabolism rate varies between individuals is influ-
enced by genomic and hormonal factors and may result in
variation in smoking behavior and response to smoking cessa-
tion therapy. In general, rapid metabolizers of nicotine are
more dependent and have poorer outcomes for cessation
attempts compared to slow metabolizers [18]. A trial of var-
enicline in heavy smokers with mild-to-moderate chronic
obstructive pulmonary disease found that extending the treat-
ment period for >12 weeks was beneficial [19].
Mental illness is associated with high rates of smoking and
these rates have remained high while smoking rates in the rest
of the population have fallen, suggesting a need for target
intervention strategies in this group. Smoking is a major cause
of premature death for people with mental illness [20]. What is
less clearly appreciated by patients and clinicians is that smok-
ing cessation brings benefit in terms of improved mental
health, a message that has a clear motivational capacity in
this group [21]. There are no clearly divergent recommenda-
tions regarding optimal strategies for smoking cessation for
people with mental illness, with some evidence to suggest
that conventional pharmacotherapies are effective. However,
there are also reports of mood fluctuation, irritability, and anxi-
ety associated with quit attempts, altered pharmacokinetics
with smoking cessation and concerns regarding other common
comorbidities including substance and alcohol dependence
[22]. Changes in CYP1A2 activity due to smoking cessation
will change the pharmacokinetics of some psychotropic agents
used in psychiatric treatment, such as clozapine. A planned
treatment strategy negotiated with the patient may be useful.
It may be necessary to change medication doses and monitor
blood concentrations. Clearly, an individualized approach to
smoking cessation is necessary within this population and
mental health services and clinicians need to have clear strate-
gies regarding how they will approach the issue of tobacco use
with their patients. There is also a need to provide NRT in
hospital settings and postdischarge support. There is a clear
need for further research investigating the effectiveness and
safety of smoking cessation therapies within this population.
Further special populations for consideration with smoking
cessation include and broad range of socially excluded and
socio-economically disadvantaged populations where smoking
prevalence remains high. Examples are ethnic and indigenous
minorities, low income, and homeless people, incarcerated peo-
ple, people with health conditions, people living in rural and
remote locations, people from the LGBTQIA community, and
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other groups. Arguably, women, young people, old people, and
people currently or previously in the military can also be con-
sidered special populations. Special populations can benefit from
individualized smoking cessation therapies for varied reasons,
including; lower motivation to quit amongst some socially
excluded populations where health literacy is poorer and public
health messages may have had less penetrance, preferences for
smoking cessation treatment in health settings that they attend
for other reasons, pharmacological reasons due to co-
medications or CYP450 phenotype. Many smokers may fit into
more than one special population category.
In developed countries where tobacco smoking prevalence has
declined, only a minority of smokers will not fit into a special
population. Some individuals who do not identify with any addi-
tional factors contributing towards smoking may have
a preference for conventional treatments, although there is evi-
dence that over the counter NRT is less effective than prescription
NRT [23], suggesting that even these individuals would benefit
from a more structured, individualized treatment. Nevertheless,
a role for easily available therapies and population-based
approaches to smoking cessation and tobacco control is likely to
remain necessary and popular into the future due to personal
PATIENT 
PRESENTS IN 
HEALTH FACILITY 
*SPECIAL GROUPS* 
• Pregnant and lactating women 
• Adolescents 
• Indigenous Peoples 
• Culturally and linguistically 
diverse 
• Mental Illness 
• Substance Misuse 
Consider the circumstances of 
these groups when prescribing. 
PREFERENCE FOR NON-PHARMACOTHERAPY
Encourage evidence-based therapies like 
Cognitive Behavioural Therapy. 
FOLLOW-UP
For each therapy, set a quit date with the patient at the time of prescription, and follow up with the patient at least within a week 
of prescription, as well as one month post-commencement. Encourage the patient to return for or seek out further advice or 
assistance as necessary. Check for side-effects and review prescription. Consider increasing or decreasing dose, or 
changing/combining prescription depending on progress.
INITIAL CONSULTATION 
Assess dependence, previous quit attempts, smoking, mental 
and physical health history, and assess any preferences or 
aversions to cessation aids along with any barriers or 
enablers to successful cessation. 
Describe options for quit aid and allow the patient time to do 
their own research before prescription as required or 
preferred. 
REAFFIRM CHOICE 
NOT TO SMOKE 
QUESTION FOR SMOKING HABITS 
‘Do you smoke tobacco products?’ 
If the patient does smoke, encourage them to seek out cessation aid. If 
the patient is seen regularly, check smoking habits on a regular basis, 
and if reticent, encourage cessation. Explain health effects of smoking, 
benefits of quitting and the options for quit aid. 
YES
NO 
NRT 
Most commonly taken, 
with the most mild side 
effect profile. 
Contraindications 
include recent heart 
problems. 
Available over the 
counter and can be 
taken in multiple forms 
concurrently or with 
Varenicline or 
Bupropion for 
increased efficacy. 
Can be taken without 
clinician supervision. 
VARENICLINE 
First choice for 
medication over 
Bupropion and 
more efficacious. 
Some evidence 
indicates severe 
potential side 
effects including 
psychosis and 
seizures. 
Contraindications 
include kidney 
problems or past 
seizures. 
BUPROPION 
Second choice for 
prescription after 
Varenicline. 
Prescription 
often depends on 
patient 
preference or 
past failure with 
Varenicline. 
Contraindications 
include past 
seizures. 
SECOND-LINE 
THERAPIES 
Includes: 
• Nortriptyline 
• Clonidine 
Prescription may 
depend on 
experiences with 
other 
pharmacotherapies, 
clinical suitability 
and patient choice. 
CONSIDER 
SPECIAL GROUPS: 
SEE *SPECIAL 
GROUPS* 
PROCEED WITH PHARMACOTHERAPY 
Encourage patient to seek out simultaneous counselling 
or behaviour support for best outcomes. Refer to a quit 
specialist, Tobacco Quitline and provide quit information. 
EMERGING 
THERAPIES 
Includes: 
• Cytisine 
• N-acetylcysteine 
• Nicotine 
Vaccines 
• Kappa 
Antagonists 
The above are 
currently under 
investigation, and 
require greater 
evidence, but may be 
used as a last 
measure. 
Figure 1. Decision tree for treatment for smoking cessation.
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preference, affordability, and availability, and ongoing need espe-
cially in countries where high rates of tobacco smoking persist.
Elements of the individualized therapies can include; treat-
ments that are tailored for a special population, treatments deliv-
ered in a preferred health setting or amongst peers, and
treatments that take into account patient characteristics and pre-
ferences. Some patients prefer to attempt to quit by themselves
and others prefer to support, where the treatment alliance
between the treating clinician and the patient becomes important
and a treatment planmay be useful. Internet-based quit resources
are valuable in this context. Planning and timing have been
demonstrated to impact the effectiveness of a smoking cessation
intervention, with planning ranging from an intention to quit,
a quit strategy, and various forms of preparatory activities and
anticipatory strategies [24]. Similarly, clinician engagement and
encouragement can drive motivation. Cross-cultural and multilin-
gual access can also be an important feature of individualized
treatment. Individualized approaches offer the ability to tailor
pharmacological intervention, provide tailored additional support,
and if desired to combine pharmacological and non-
pharmacological approaches for smoking cessation. However,
individualized approaches remain limited due to a paucity of high-
quality smoking cessation effectiveness data for special
populations.
4. Conclusion
Starting with the introduction of the nicotine patch in 1984,
smoking cessation pharmacotherapy has made modest pro-
gress in the last three decades. NRT has been formulated in
multiple ways and two further agents, varenicline and bupro-
pion, have gained regulatory approval. Although most smokers
have some degree of motivation to quit, most quit attempts
end in relapse within 12 months of quitting. Reduction in
tobacco prevalence is largely attributable to public health inter-
ventions and regulatory interventions rather than smoking ces-
sation interventions. Efforts to prevent smoking onset in young
people are important. More effective smoking cessation inter-
ventions are also required. Individualized tailored approaches
are likely to become more prominent in the future because as
tobacco prevalence declines the remaining smokers often have
complex problems, new interventions that can better target
individuals are being developed, new pharmacotherapeutic
strategies are emerging that may have advantages in special
populations, and personal preference will sometimes favor an
individualized approach. However, further research is required
to develop interventions that target special populations and
assess their effectiveness and safety. Conventional, non-
individualized pharmacotherapeutic interventions will retain
an important role in countries with high tobacco prevalence
and will continue to have a role elsewhere. Public health stra-
tegies and regulatory interventions are likely to continue to be
strong drivers of the further reduction in tobacco prevalence.
5. Expert opinion
Since the introductionof nicotine patches in 1984, therehavebeen
new formulations of NRT and the emergence of two new agents,
varenicline and bupropion, that have obtained regulatory
approval. Treatment effectiveness has not measurably changed
in this period. Although pharmacotherapeutic intervention is
superior to placebo at treatment endpoint in clinical trials, relapse
rates after successfully quitting smoking remain high.
Contemplation of quitting and quit attempts are common
amongst smokers, suggesting that difficulties in quitting and
relapse are a greater problem thanmotivating smokers to attempt
to quit. Reduction in tobacco prevalence is attributable mainly to
public health strategies and regulatory interventions rather than
smoking cessation treatment. At a population level, fewer young
people are taking up smoking compared to previous generations
and current smokers have a higher mortality rate compared to
age-matched non-smokers, resulting in lower population preva-
lence of current smokers.
It is unclear to what extent tobacco prevalence can be further
reduced through public health messages and regulatory interven-
tions and these strategiesmay be self-limiting, requiring collabora-
tion between public health, regulatory, and smoking cessation
researchers to achieve a common goal of reducing tobacco pre-
valence. This is likely to require targeted interventions. Public
health messages and regulatory interventions have been less
effective in some socially excluded and socio-economically disad-
vantaged populations. High rates of smoking persist in popula-
tions including; the mentally ill, incarcerated people, and some
minority groups. Individualized approaches are like to have
a greater role in the foreseeable future. Individualized therapies
may include currently approved pharmacotherapies and other
pharmacotherapies currently being investigated. Individualized
strategies are limited by a paucity of high-quality data investigat-
ing the effectiveness and safety of targeted interventions in special
populations and further research is long overdue.
Conventional, non-individualized strategies are likely to
persist into the future. They are low-cost, easily accessible
options, and may be preferred by some individuals.
It is possible that novel agents have a role in future inter-
ventions. This may be as monotherapies where they may have
safety advantages in special populations, including women
during pregnancy and breastfeeding and for people with
mental or physical comorbidities or as combination therapies
where they may enhance treatment effectiveness. Agents such
as N-acetylcysteine, cytisine, nicotine vaccines, and kappa
antagonists may have a potential role.
Individualized strategies and novel therapies may result in
a greater quit rate, but their impact on the relapse rate remains
unclear. Further research is required to improve relapse preven-
tion, whichmay include novel or conventional pharmacotherapies
or combinations of pharmacological and non-pharmacological
strategies. Our opinion is that a pluralized approach to smoking
cessation, that encompasses individualized settings and persona-
lized approaches, as well as conventional and novel therapies, as
well as an emphasis on public health interventions, will all have
a role in the future. Individualized settings and personalized
approaches receive more attention in countries that have experi-
enced significant falls in rates of tobacco use where smoking rates
remain high in special populations only. The future direction of
smoking cessation strategies remains largely determined by pol-
icymakers whose considerations include the impact of an inter-
vention of the rates of tobacco use at a population level as well as
benefits to individuals and special populations.
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The role of harm minimization strategies, such as substitut-
ing tobacco cigarettes for ENDS, is controversial and its asso-
ciation with the tobacco industry leads to suspicion. However,
harm minimization strategies are common for other addictive
substances and further research is likely. It is our opinion that
a harm minimization option may be beneficial for some smo-
kers who do not intend to quit; however, the tobacco industry
should not have a role in the provision of any option.
In coming years the emphasis on individualized strategies
is likely to increase, especially as smoking prevalence
decreases and remaining smokers are more likely to have
complex issues to address. There will also be a greater focus
on cessation interventions that include relapse prevention and
clinical trials with long follow up period to investigate whether
participants remain abstinent. New formulations of existing
pharmacotherapies are likely to be developed. Novel therapies
will continue to attract interest from researchers and some of
these may transit into clinical practice.
No breakthrough pharmacotherapies leading to decisive
changes in smoking cessation outcomes are on the horizon;
however, some improvements in outcomes should be expected.
Public health and regulatory interventions will continue to be the
main drivers of further falls in tobacco prevalence.
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